<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985058</url>
  </required_header>
  <id_info>
    <org_study_id>RWD_abemaciclib</org_study_id>
    <nct_id>NCT04985058</nct_id>
  </id_info>
  <brief_title>Real-world Data in Patients With Advanced Breast Cancer Treated With Abemaciclib</brief_title>
  <official_title>Real-world Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will assess real-world clinical outcomes and adverse events from treatment&#xD;
      with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative&#xD;
      advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Through the completion of the study, for an average of 6 months</time_frame>
    <description>the time from treatment initiation to either the first documented disease progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months</time_frame>
    <description>the time from treatment initiation to patient death or last contact</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with advanced breast cancer</arm_group_label>
    <description>Patients with advanced breast cancer treated with abemaciclib in combination wih endocrine treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer&#xD;
        treated with abemaciclib in combination with endocrine therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed HR-positive, HER2-negative advanced breast cancer&#xD;
&#xD;
          -  Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of&#xD;
             oncology&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Any menopausal status&#xD;
&#xD;
          -  Treatment with abemaciclib in combination with endocrine therapy&#xD;
&#xD;
          -  Any endocrine therapy&#xD;
&#xD;
          -  At least two months of treatment with abemaciclib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Fountzilas, MD, PhD</last_name>
    <phone>+306945779709</phone>
    <email>FOUNTZILA@ONCOGENOME.GR</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Areti Stamboliou</last_name>
    <phone>+302106912520</phone>
    <phone_ext>23</phone_ext>
    <email>a_stampoliou@hecog.ondsl.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hellenic Oncology Cooperative Group</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Fountzilas, MD</last_name>
      <email>fountzila@oncogenome.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abemaciclib</keyword>
  <keyword>real-world data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

